Juno Bio Raises $3.8M and Opens First CLIA Lab for Vaginal Microbiome Testing

For decades, standard vaginal health diagnostics have relied on PCR panels and culture methods that test for a short, predetermined list of suspects. The result, according to Juno Bio’s data, is that 67.5% of patients with vaginal complaints are misdiagnosed, underdiagnosed, or overdiagnosed . Now a new breed of diagnostic company is betting on a different approach: next-generation sequencing (NGS) that scans everything at once, without assumptions.

On July 16, 2026, Juno Bio announced a $3.8 million seed round backed by Ada Ventures (lead), Artesian, Entrepreneur First, and Illumina Accelerator, alongside the opening of its first CLIA-certified sequencing lab in Oakland, California — a facility the company says is the first built entirely for women’s health . The lab processes Juno’s at-home vaginal microbiome test in-house, ending the company’s reliance on third-party labs and bringing clinical-grade sequencing closer to the patient .

How the Platform Works

Juno Bio uses next-generation sequencing (NGS) — not standard PCR — to comprehensively profile the vaginal microbiome. Unlike targeted PCR tests, NGS does not predetermine which organisms to look for. It captures DNA and RNA from the full microbial community, identifying both expected and unexpected bacteria, fungi, and co-infections .

From a single at-home swab, the test screens for:

• Approximately 10,000 bacteria and fungi (the company states the assay covers over 45,000 microbes across all known species, depending on how strains are counted) .
• Four common STIs, including chlamydia and gonorrhea, alongside the full microbiome profile .

Results are delivered through a private dashboard, and patients can book a free one-on-one call with a vaginal health coach to discuss findings and next steps . The test is available in 46 states, priced at $149 for a single test or $99 per test on a subscription basis .

Why NGS Matters for Misdiagnosis and Co-Infections

The breadth of NGS is its key clinical advantage. Standard PCR panels typically test for 3–5 organisms, which can miss polymicrobial infections — conditions where multiple pathogens are present simultaneously, such as mixed bacterial vaginosis and yeast infections. Because Juno Bio’s test captures everything without pre-selection, it can identify co-infections that standard care would overlook .

The company reports that its CLIA laboratory results show over 92% concordance with hospital clinical culture methods, compared to 60-70% for typical direct-to-consumer tests .

Fertility and Menopause: Beyond Infection Detection

Juno Bio’s platform also addresses reproductive and hormonal health conditions linked to the vaginal microbiome.

• Fertility: Research shows that disrupted vaginal microbiomes can affect IVF success rates and contribute to recurrent infections and infertility . Juno Bio’s test profiles the microbial community to identify dysbiosis patterns that may interfere with conception.
• Menopausal health: Hormonal changes during menopause alter the vaginal microbial balance, often leading to atrophy-related dysbiosis. The test quantifies these shifts, giving clinicians data to guide treatment for symptoms like dryness, irritation, and recurrent infections .

What the $3.8M Funds

The seed funding directly supports Juno Bio’s transition from a research-stage company to a clinical infrastructure provider. The new Oakland lab enables the company to:

• Scale its CLIA-certified sequencing capacity without relying on external labs .
• Process larger volumes of at-home test kits for patients across 46 states .
• Build one of the largest repositories of vaginal microbiome data for future research and diagnostic development .

Investors include Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator — the same accelerator that backed Juno Bio in its earlier 2019 round .

The Bottom Line

Juno Bio is positioning itself not as a consumer wellness brand but as a clinical diagnostic infrastructure company. By bringing NGS-based testing in-house and achieving CLIA certification, it aims to close the gap between what standard care misses and what precision sequencing can reveal — from hidden co-infections to fertility-linked dysbiosis to menopausal microbial shifts. The $3.8M round and new lab mark a step toward making broad-spectrum vaginal microbiome testing a standard part of women’s healthcare.